Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA XL vs CARDURA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
Hypertension,Benign prostatic hyperplasia
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
98-99% bound to plasma proteins (primarily albumin).
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Safety and efficacy not established in pediatric patients; use not recommended.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
None.
None
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to doxazosin or other quinazolines
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
No interactions on record
No interactions on record
Common clinical questions about CARDURA XL vs CARDURA, answered by our medical review team.
CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA XL and CARDURA depend on the specific clinical indication. These are both Alpha-1 Blocker Antihypertensive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA XL and CARDURA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.